Our study comprehensively characterizes the novel regulatory mechanism underlying H3K18la-driven KRT19 promotes NSCLC progression, yields promising insights into combination treatment strategies for patients with NSCLC. Here, KRT19 is linked to non-small cell lung carcinoma.